Publications

Is time to access novel cancer therapies in Asia accelerating? A preliminary investigation

Download file
CAR-T cell therapy: implications of recent Yescarta and Kymriah announcements for manufacturers and assessment agencies

Download file
CADTH issues its first CAR-T assessment

Download file
Impact of European Medicines Agency clinical trial transparency policies on HTA decisions in the UK

Download file
Can we satisfactorily measure the clinical value of new classes of oncology agents with a single summary measure?

Download file
Do countries with similar GDPs and health expenditures reimburse the same cancer drugs?

Download file
What role does the patient perspective play in determining access to innovative therapies?

Download file
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European panel study

Download file
The role of companion diagnostics in HTAs of drugs in France, Germany, and the UK

Download file
Measuring survival benefit in health technology assessment in the presence of nonproportional hazards

Download file
What is the impact of orphan drug re-assessments in Germany on their additional benefit and price?

Download file
The difference between regulatory and market access decisions on treatment availability for new drugs in six common cancers across Australia, Canada, and Europe

Download file
Mapping patient involvement in NICE appraisals of oncology products

Download file
Impact of EMA clinical trial transparency policies on HTA decisions in Germany

Download file
Do market withdrawals impact patient access to treatment in Germany?

Download file
Can we satisfactorily measure the clinical value of new classes of oncology agents with a single summary measure?

Download file
Assessing the implications of the NICE budget impact test: how many oncology regimens will be affected and what will be the impact on patient outcomes?

Download file

You have a vision; we are the consulting partner that will get you there.
We would be delighted to have a confidential conversation about your market access needs.